Create account

Coverage dated September 12, 2023

Moderna says mRNA flu shot generates better immune response in study than currently available vaccine

Headline from KTVZ Bend

By Meg Tirrell, CNN (CNN) — Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 study, paving the way for the company to discuss a path to approval with …

KTVZ Bend's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

8 articles, oldest first.

  1. KTVZ Bend

    Moderna says mRNA flu shot generates better immune response in study than currently available vaccine (opens KTVZ Bend)

    Published

    KTVZ Bend's feed description

    By Meg Tirrell, CNN (CNN) — Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 study, paving the way for the company to discuss a path to approval with …

  2. ABC 7 Chicago

    Moderna says mRNA flu shot has better immune response in study than currently available vaccine (opens ABC 7 Chicago)

    Published

    ABC 7 Chicago's feed description

    Moderna and Pfizer have plans to combine Covid-19 mRNA shots with those for flu and RSV in the years ahead if studies show that they're safe and effective.

  3. NBC New York

    Moderna says flu vaccine showed promising results in phase three trial, paving path to approval (opens NBC New York)

    Published

    NBC New York's feed description

    Moderna compared the flu vaccine, dubbed mRNA-1010, to a currently approved seasonal flu vaccine from GlaxoSmithKline called Fluarix.

  4. Investopedia

    Moderna Reports Successful Trial of Flu Vaccine, Plans More Treatments Ahead (opens Investopedia)

    Published

    Investopedia's feed description

    Moderna (MRNA) was the best-performing stock in the S&P 500 as the vaccine maker reported its experimental flu shot met its primary endpoint in a Phase 3 trial.

  5. WHDH Boston

    Moderna says mRNA flu shot generates better immune response in study than currently available vaccine - Boston News, Weather, Sports (opens WHDH Boston)

    Published

    WHDH Boston's feed description

    (CNN) — Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.

Moderna says mRNA flu shot generates better immune response in study than currently available vaccine | Since Then